Aclaris Therapeutics Inc

NASDAQ:ACRS 4:00:00 PM EDT

7.90

-0.34 (-4.13%)

7:57:53 PM EDT: $7.68 -0.22 (-2.79%)

Market Cap (Intraday)	526.85M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.75 Million
Adjusted EPS	-$0.44

See more estimates

10-Day MA	$8.33
50-Day MA	$13.03
200-Day MA	$15.09

See more pivots

Aclaris Therapeutics Inc Stock, NASDAQ:ACRS

640 Lee Road, Suite 200, Wayne, Pennsylvania 19087

United States of America

Phone: +1.484.324.7933

Number of Employees: 105

http://www.aclaristx.com

Description

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.